… The aim of the present study was to evaluate the clinical outcomes and therapeutic strategies
for hematological malignancies associated with FGFR1 rearrangement. In previous reports…

… whether the angiogenic factors (vascular endothelial growth factor (VEGF), platelet-derived …
We selected three growth factors and two angiopoietins in an attempt to understand whether …

The expression of epidermal growth factor receptor (EGFR), oestrogen receptor (ER) and
progesterone receptor (PR) was assayed by a radioreceptor method in 117 primary ovarian …

… the predictive value of early metabolic imaging with respect to traditional clinical outcomes.
… -Farber Cancer Institute who were blinded to clinical outcome data. Up to five target lesions …

… epidermal growth factor receptor (EGFR) mutation. However, the clinical outcomes among the
… We aimed to evaluate clinical outcomes and secondary EGFR T790M mutation among the …

… In this study, we tested the potential use of measuring plasma insulin-like growth factor …
Discriminative assessment of levels of preoperative plasma insulin-like growth factor binding …

… The most important pathways involved in oncogenesis downstream to growth factor …
endothelial growth factor (VEGFR) receptor families. Autocrine and paracrine growth factor loops are …

… factor receptor (EGFR), and HER2 expressions have been linked to clinical outcomes in
several solid tumors. However, the clinical significance of these biomarkers in gastric cancer (GC…

… Therapies were classified as vascular endothelial growth factor (VEGF)/vascular
endothelial growth factor receptor (VEGFR) or mammalian target of rapamycin inhibitors (mTORi). …

… IL-6, IL-8, IL-16) and tumor necrosis factor alpha (TNF α); Injury and Repair Biomarkers (IRB):
vascular endothelial growth factor (VEGF) and matrix metalloproteinase nine (MMP-9) and …